Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer anti-smoking agent EU approval

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

European authorities approve Pfizer's novel smoking agent varenicline Sept. 26 under the trade name Champix. Varenicline was approved in the U.S. May 10 under the trade name Chantix (1Pharmaceutical Approvals Monthly May 2006, p. 5). Pfizer had sought to use the Champix name in the U.S. as well, but FDA review documents said the name was "overly fanciful and overstates the efficacy of the product" (2Pharmaceutical Approvals Monthly July 2006, p. 27)...

You may also be interested in...

Approvals In Brief

Pfizer's Chantix for smoking cessation: Labeling for Pfizer's newly approved selective nicotinic acetylcholine receptor partial agonist Chantix (varenicline) for smoking cessation includes superiority claims over GlaxoSmithKline's Zyban (bupropion). In one study, 44% of Chantix patients were abstinent in treatment weeks nine through 12 compared to 30% of Zyban patients and 17% on placebo, labeling says. Additionally, 29% of Chantix patients were continuously abstinent through the end of treatment compared to 23% of Zyban patients. On May 10, Chantix (formerly Champix) became the first nicotine agonist approved by FDA and the first new prescription medication approved for smoking cessation in nearly a decade. Roll-out of the tablet therapy is slated for the second half of the year...

FDA To Ramp Up ASCA Pilot In 2021

A report from the US FDA says the agency will focus on updating its premarket submission portal, training staff and taking additional steps to start taking in applications for ASCA pilot participant sponsors.

Scotland's MGB Plots Phase III For Promising Antibacterial

With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts